Sanofi nominates Professor Bonnie L. Bassler to its Board of Directors
you think this is good for their diabetes franchise?
I disagree.No reassurance needed. They will significantly talk about their strategy in diabeties. From their website their AGENDA itself is about Toujeo and Afrezza
The agenda will consist of several deep dive sessions on new medicines and vaccines that we expect to launch in 2015, such as alirocumab, Dengue vaccine, Toujeo® and Afrezza®. A high level update on the next wave of innovative medicines and vaccines will also be provided.
excerpt from rueters- ANYBODY EXCITED???
Sanofi said last month it faced tough times with its top-selling insulin Lantus in the United States - and its pricing power is set to shrink further as so-called biosimilar copies enter the market over the next two years.
Sanofi stockholders are thus likely to press for answers on the prospects of its longer-acting version of Lantus, dubbed Toujeo, and of an inhaled insulin called Afrezza.
"They have a lot going for them. It's not a bad company," said Geir Lode, head of Hermes Global Equities, which owns Sanofi stock. He says the group needs to clearly spell out its strategic intentions, from diabetes to mergers and acquisitions.
"It's all about clarification. I feel like I'm walking in the fog now, I see nothing and I need the sun to come out."
reported their 13F -- ending Sept 30.
MNKD 3,250,000 SHARES - PUT
Means they increased their PUT by a half million from June; however the "HIT" piece where he re-iterated the $1 price target was dated October 31, 2014. Thus, I still suspect he will cover very shortly and he will do so in dramatic fashion before end of year. BE WARNED SHORTY.
I don't know if he is under pressure, but I do know I will not belive him ever!
When I first started investing, I used to belive that Cramer was trying to help the fellow retailer from navigating through wall street. He turned out to be quite te liar and flip flopper. He would recommend stocks after they already made moves and would invite CEOs who's stocks he wanted to recommend, then a few months later he would completely go against the company as if he never recommended them. That's when I knew he was simply pumping and dumping or dumping and pumping at the cost of retailers. Adam is exactly the same except he tweets and focuses on bio companies. The obvious thing for the retailer is not to trust any of them. Go with your numbers, go with your own due diligence. Weed through the information overload and BS oinions and then make your decisions!! GO Mannkind!
yes we are cocky longs, you must literally be short, no wonder you hate the world!
don't worry there are pumps that can simulate growth.
yes that is what everyone is wondering. I for one don't think they know any more than any of us. In fact we have a distinct advantage in that we know what the product is capable of. a short only bets against the stock so that they can profit on the price decline. they know NOTHING about the company!